VasoDynamics Presents Phase-1b NG11-2 Clinical Data at ESTRO Conference

At the recent ESTRO conference in Glasgow on 3-7 May 2024, VasoDynamics presented the preliminary findings from its Phase-1b Study with NG11-2.

May 9th, 2024|

VasoDynamics Receives Global Health & Pharma Biotechnology 2024 Award

VasoDynamics receives Global Heath & Pharma Biotechnology Award 2024 as Best Cancer Care Solutions Provider 2024 - UK

April 10th, 2024|

Laboratory facilities initiated to optimise development of product pipeline for the prevention of cancer therapy induced side-effects

March 28th, 2024|

A Phase-1b Dose Escalation Study to Assess the Effect of NG11-2 on Radiation Induced Oral Mucositis (RIOM) in Patients with Head & Neck Cancer

March 4th, 2024|

Preclinical team strengthened to optimise development of NG13 for the prevention of chemotherapy-induced alopecia

February 8th, 2024|

New treatments for the prevention of the side-effects from anti-cancer therapy

February 7th, 2024|